text: August 29th 2024
  The decision follows phase 3 EV-302 trial findings showing improved survival with enfortumab vedotin plus pembrolizumab vs chemotherapy in urothelial cancer.
  Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
  Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
  Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
  Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
  18th Annual New York GU Cancers Congress™
  March 28-29, 2025
  Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care